Stoke Therapeutics, Inc.
$36.46
▲
2.34%
2026-04-21 09:38:02
www.stoketherapeutics.com
NMS: STOK
Explore Stoke Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.16 B
Current Price
$36.46
52W High / Low
$40.22 / $7.34
Stock P/E
—
Book Value
$5.98
Dividend Yield
—
ROCE
-5.71%
ROE
-2.37%
Face Value
—
EPS
$-0.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
170
Beta
1.22
Debt / Equity
1.18
Current Ratio
5.28
Quick Ratio
5.28
Forward P/E
-10.81
Price / Sales
11.01
Enterprise Value
$1.75 B
EV / EBITDA
-92.99
EV / Revenue
9.49
Rating
None
Target Price
$45.1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 2. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 3. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 4. | Metagenomi Therapeutics, Inc. | $1.53 | — | $55.68 M | — | -48.45% | -44.66% | $3.95 / $1.25 | $4.22 |
| 5. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 6. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
| 7. | Relmada Therapeutics, Inc. | $7.37 | — | $773.03 M | — | -67.49% | -25.62% | $7.94 / $0.27 | $1.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.4 M | 10.63 M | 13.82 M | 158.57 M | 22.61 M | — |
| Operating Profit | -61.44 M | -43.09 M | -27.3 M | 111.24 M | -13.65 M | — |
| Net Profit | -57.93 M | -38.35 M | -23.48 M | 112.88 M | -10.48 M | — |
| EPS in Rs | -0.98 | -0.65 | -0.4 | 1.91 | -0.18 | -0.47 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 184.42 M | 36.55 M | 8.78 M | 12.4 M |
| Operating Profit | -20.59 M | -101.37 M | -114.77 M | -104.36 M |
| Net Profit | -6.88 M | -88.98 M | -104.7 M | -101.07 M |
| EPS in Rs | -0.12 | -1.5 | -1.77 | -1.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 418.43 M | 271.56 M | 228.34 M | 256.07 M |
| Total Liabilities | 65.98 M | 42.53 M | 68.78 M | 71.22 M |
| Equity | 352.46 M | 229.02 M | 159.56 M | 184.85 M |
| Current Assets | 305.7 M | 232.76 M | 215.34 M | 244.07 M |
| Current Liabilities | 57.88 M | 40.06 M | 30.82 M | 31.39 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 45.59 M | -86.85 M | -81.07 M | -31.87 M |
| Investing CF | -186.81 M | -107.47 M | 105.95 M | -45.88 M |
| Financing CF | 97.39 M | 131.09 M | 53.01 M | 46.41 M |
| Free CF | 44.91 M | -87.05 M | -82.68 M | -35.83 M |
| Capex | -0.67 M | -0.2 M | -1.62 M | -3.96 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 316.34% | -29.22% | — | — |
| Earnings Growth % | 15.01% | -3.59% | — | — |
| Profit Margin % | -243.42% | -1192.47% | -814.73% | — |
| Operating Margin % | -277.31% | -1307.21% | -841.24% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -271.36% | -1279.09% | -828.78% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.